Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TMC278 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | TMC278 One 25 mg tablet once daily for 11 days (TrtA and C) |
| 002 | EXPERIMENTAL | Raltegravir One 400 mg tablet twice daily for 4 days (Trt B) and for 11 days (TrtC) |
| Name | Type | Description |
|---|---|---|
| TMC278 | DRUG | One 25 mg tablet, once daily, for 11 days (TrtA and C) |
| Raltegravir | DRUG | One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC) |
Inclusion Criteria: * Healthy, based on physical examination, medical history, vital signs, ECG, blood biochemistry, hematology and urinalysis * Body Mass Index of 18 to 30.0 kg/m2 * Non-smoking for at least 3 months prior to screening * Women must be postmenopausal for at least 2 years, or be surg...
Top 20 of 28 competitors
TMC278 is an investigational small molecule being studied for the treatment of HIV Infections. It is currently in Phase 1 clinical development. The drug is being evaluated for its potential role in managing HIV, though it is not yet approved and remains under investigation.
TMC278 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this investigational drug for HIV Infections, and it is currently in Phase 1 development.
TMC278 is in Phase 1 clinical development. It is an investigational drug for HIV Infections and has not been approved. One Phase 1 study has been completed, and the drug remains under evaluation in early-stage clinical research.
TMC278 has one completed clinical trial, NCT01288755, titled "TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir." This Phase 1 study enrolled 24 participants and was a controlled, randomized trial in healthy volunteers.
TMC278 is a small molecule being studied for HIV Infections. Its specific molecular target has not been disclosed in available information. The drug is in Phase 1 development by Merck & Company, Inc., and its mechanism of action is not publicly detailed.